Urgent care was notoriously overlooked as a key contributor early in the fight against the COVID-19 pandemic, first as a testing resource and then as a powerful partner in vaccination campaigns. At least one urgent care company is ensuring that the industry will be represented in research into not only preventing the virus, but also establishing definitive treatments for ill patients. Houston-based Next Level Urgent Care says it is launching three clinical trials to evaluate the efficacy of a new investigational study drug developed by Pfizer. The pill is purported to be an alternative therapy that minimizes severity of symptoms in patients who have tested positive for SARS-CoV-2, as well as a preventative option for individuals who have been exposed to someone with the virus. Next Level already offers monoclonal antibody infusions at some locations.
Research into Preventing and Treating COVID-19 Continues—and Urgent Care Has a Seat at the Table